EC Number   |
Application |
Reference |
|---|
   2.7.11.10 | analysis |
development of real-time imaging for continous enzyme detection and kinetics in intact cells and living mice utilizing a recombinant IkappaBalpha-firefly luciferase reporter construct, system can be used for determination of kinetics/pharmacodynamics of potential selective inhibitors, and for investigations of NF-kappaB signalling pathway activation |
662931 |
| 2.7.11.10 | drug development |
because of its central role in the overall NF-kappaB regulation, IKK-2 is a viable target for drug discovery |
723696 |
| 2.7.11.10 | medicine |
17-acetoxyjolkinolide B is a novel type NF-kappaB pathway inhibitor. Its unique interaction mechanism with IKK may render it a strong apoptosis inducer of tumor cells and a novel type anticancer drug candidate |
694114 |
| 2.7.11.10 | medicine |
enzyme expression is negatively correlated with the invasiveness, migration, and angiogenesis of nasopharyngeal carcinoma cells |
739047 |
| 2.7.11.10 | medicine |
Helicobacter pylori-mediated gastric inflammation critically depends on the efficient recruitment and activation of macrophages, with sufficient NF-kappaB activation |
692604 |
| 2.7.11.10 | medicine |
IKK activates TNFalpha-dependent signaling pathways inducing drug resistance, e.g. increasing cell survival in anti-cancer treatment with 5-fluoro-2'-deoxyuridine, overview |
662448 |
| 2.7.11.10 | medicine |
IKK is thought to be a focal target of drug development |
704348 |
| 2.7.11.10 | medicine |
IKK2 inhibition represents a promising strategy for the treatment of advanced stages of cutaneous T-cell lymphomas |
703253 |
| 2.7.11.10 | medicine |
IKKalpha is responsible for the development of acantholytic squamous cell carcinoma (ASCC), a human SCC variant |
691676 |
| 2.7.11.10 | medicine |
IKKbeta inhibitors are utilized for the treatment of cancer and immunological disorders |
702590 |
